Article

Brimonidine/timolol receives FDA approval

Irvine, CA-Brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution (Combigan, Allergan Inc.), an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, has been approved by the FDA for the reduction of elevated IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Irvine, CA-Brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution (Combigan, Allergan Inc.), an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, has been approved by the FDA for the reduction of elevated IOP in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The company expects the prescription eye drop to be available to physicians in the fourth quarter of this year.

“Many patients require more than one medication to meet their target IOP,” said E. Randy Craven, MD, director, Glaucoma and Cataract Consultants of Colorado, Littleton, and associate clinical professor of ophthalmology, University of Colorado School of Medicine, Denver. “With [brimonidine/timolol], it is exciting to be able to offer patients two strong agents in one bottle.”

In the 12-month pivotal trials in which Dr. Craven was involved, brimonidine/timolol significantly reduced mean IOP up to 7.6 mm Hg from baseline and was well-tolerated. Clinical studies found that the fixed-combination therapy provided additional IOP lowering versus either brimonidine or timolol used alone. The new drug, administered twice a day, provided an additional 1 to 3 mm Hg decrease in IOP over brimonidine treatment three times a day and an additional 1 to 2 mm Hg decrease over timolol treatment twice a day. The IOP lowering of the new drop dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution 0.2% dosed three times per day.

The eye drop is contraindicated in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease; in patients with sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock; and in patients with hypersensitivity to any component of the product. The most common adverse reactions, occurring in approximately 5% to 15% of patients, included allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, and ocular burning and stinging.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.